A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (PAH) (MK-7962-024)
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 164 participants.
Also called NCT06664801
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; single masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 164 participants
- Sponsor
- Registry
-
NCT06664801 -
2024-512278-92-00 -
U1111-1304-7985 -
jRCT2061240077
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- United States, Argentina, Australia, Canada, China, Colombia, Czechia, France, Germany, Hungary, Israel, Italy, Japan, Netherlands, Poland, Singapore, South Korea, Spain, Taiwan, Thailand, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT06664801. Randomized; single masking; primary purpose treatment. Start 2024-11-14 (actual); primary completion 2025-11-20 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (PAH) (MK-7962-024)
- Acronym
- LIGHTRAY
- Condition
- Pulmonary Arterial Hypertension
- Intervention (Biological)
- Sotatercept
- Intervention (Biological)
- Background PAH Therapy
- Lead sponsor
- Merck Sharp & Dohme LLC
Record details
- Record id
cardio:ct-nct06664801- Content hash
053dc07485676b74a63d78a701a350e15ecc445e1800a9ab66e2875f3e32ad99